© Copyright - Newspaper WordPress Theme by TagDiv
Dutasteride
Also known as / Synonyms: Dutasteride, Dual 5-AR Inhibitor, BPH Antiandrogen
Dual 5-alpha reductase inhibitor capsule that blocks DHT, shrinks an enlarged prostate (BPH), and reduces urinary retention risks.
Clinical Snapshot & Specifications
Approved Indications & Medical Uses
- Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
- Reduction of the risk of acute urinary retention (AUR) and the need for BPH-related surgical intervention (e.g., TURP).
- Combination therapy with tamsulosin for the treatment of moderate to severe BPH.
- Off-label: treatment of male androgenetic alopecia (hair loss) in adult men unresponsive to minoxidil or finasteride.
Contraindications (Do Not Use If…)
- Pregnancy and women of childbearing potential (BLACK BOX TERATOGEN WARNING: causes feminization of male fetuses).
- Pediatric patients.
- Known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors (finasteride), or formulation excipients.
Important Clinical Precautions & Warnings
- CRITICAL TERATOGENIC RISK TO MALE FETUS: dutasteride is absorbed through the skin; women who are pregnant or may become pregnant must NOT handle leaking capsules; causes abnormal development of external genitalia in male fetuses.
- Blood donation restriction: men taking dutasteride must not donate blood until at least 6 months after their last dose to prevent transfusion to pregnant recipients.
- Prostate-Specific Antigen (PSA) reduction: dutasteride reduces baseline serum PSA by approximately 50% after 3 to 6 months of therapy; double the measured PSA value when screening for prostate cancer.
- High-grade prostate cancer: clinical trials (REDUCE study) observed a small increase in the diagnosis of high-grade prostate cancer (Gleason score 8-10) in men taking 5-AR inhibitors.
- Extremely long elimination half-life (~5 weeks): drug levels remain detectable in serum for up to 4 to 6 months after drug discontinuation.
- Rule out prostate cancer prior to initiating therapy for BPH.
Special Populations (Paediatric & Geriatric Care)
Pediatric: Strictly contraindicated in children. Geriatric: No dosage adjustment necessary; highly effective for elderly men with marked prostatic enlargement (> 30-40 cc).
Side Effects & Adverse Reactions
Common Side Effects (Usually Mild)
Erectile dysfunction, decreased libido, ejaculation disorders (decreased ejaculate volume), gynecomastia (breast tenderness/enlargement), and dizziness.
Serious Side Effects — Seek Urgent Medical Care
Increased risk of high-grade prostate cancer, severe male fetal genital abnormalities (teratogenic exposure), male breast cancer (rare reports), and severe hypersensitivity reactions (angioedema).
Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.
Drug, Food & Substance Interactions
- Potent CYP3A4 inhibitors (ketoconazole, ritonavir, verapamil, diltiazem): increase serum dutasteride concentrations; use caution during chronic co-administration.
- No clinically significant interactions with tamsulosin, warfarin, digoxin, or cholestyramine.
Pregnancy & Lactation Clinical Safety
Pregnancy Safety:
STRICTLY CONTRAINDICATED IN PREGNANCY (FDA Category X). Inhibits the conversion of testosterone to DHT, which is essential for normal development of male fetal genitalia. Exposure results in hypospadias, micropenis, and cryptorchidism in male fetuses.
Lactation & Breastfeeding:
Contraindicated in women. Excretion in human milk is unknown.
Storage, Administration & Overdose Protocol
🌡️ Recommended Storage:
Store capsules at 20°C to 25°C (68°F to 77°F). Do not open, crush, or chew capsules (contact with contents irritates oropharyngeal mucosa).
⏱️ Missed Dose Protocol:
Take the missed 0.5 mg capsule as soon as remembered. If close to the next scheduled dose, skip and resume regular daily schedule. Do not take extra capsules.
Doses up to 40 mg/day (80 times the therapeutic dose) for 7 days have been administered without significant adverse effects. No specific antidote exists; provide supportive monitoring in view of the 5-week elimination half-life.
